Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 7/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745875 | 0.99 | PDK2 (0.34) | PDK2TGFBR1FEN1CYP1A2CYP2C19 | |
| SCHEMBL4745879 | 0.99 | PDK2 (0.34) | PDK2TGFBR1FEN1CYP1A2CYP2C19 | |
| SCHEMBL4746419 | 0.98 | TGFBR1 (0.34) | PDK2TGFBR1FEN1CYP1A2CYP2C19 | |
| SCHEMBL4746429 | 0.97 | TGFBR1 (0.33) | PDK2TGFBR1FEN1CYP1A2CYP2C19 | |
| SCHEMBL4746145 | 0.94 | PDK2 (0.36) | PDK2TGFBR1FEN1CYP1A2CYP2C19 | |
| SCHEMBL4745865 | 0.93 | FEN1 (0.36) | PDK2TGFBR1FEN1 | |
| SCHEMBL4746105 | 0.90 | PDK2 (0.34) | PDK2TGFBR1CYP1A2CYP2C19KMT2A | |
| SCHEMBL13320380 | 0.89 | PDK2 (0.37) | PDK2TGFBR1FEN1CYP1A2CYP2C19 | |
| SCHEMBL13320367 | 0.84 | ALDH1A1 (0.35) | PDK2TGFBR1CYP1A2CYP2C19KMT2A | |
| SCHEMBL4746287 | 0.83 | PTPRC (0.39) | TGFBR1FEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173275-B2 | Azaindenochrysene derivative and organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173275-B2 | Azaindenochrysene derivative and organic light-emitting device | CANON KABUSHIKI KAISHA (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | CANON KABUSHIKI KAISHA (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100117526-A1 | NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE | NR2E3, OR51E2, AZI2 | PDK2 4048/4885TGFBR1 1895/4885FEN1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.